Minovia Therapeutics Appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as Board Member

TIRAT HACARMEL, Israel, Jan. 5 (Korea Bizwire) – Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a [...]

Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023

WOBURN, Mass. and HAIFA, Israel, Jan. 3 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Time: 9:45 AM PST Track: Franciscan C (Ballroom Level) Biotech [...]

Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases

WOBURN, Mass. and HAIFA, Israel, Dec. 21 (Korea Bizwire) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine. The study was conducted in collaboration with global leaders [...]